Theresa Matkovits, Ph.D.

Theresa Matkovits, Ph.D. has a strong background in the biopharmaceutical industry and has held various leadership roles throughout their career. In 2010, they joined The Medicines Company as Vice President and Innovation Leader for Infectious Disease, where they played a key role in developing and executing strategies for a novel anti-infective drug. Theresa also led the recruitment of senior leadership and built operational infrastructure for the company's infectious diseases business franchise.

In 2014, Matkovits joined NPS Pharmaceuticals as a Research and Development Program Leader, where they successfully led two programs through FDA approval and commercialization. Theresa also played a pivotal role in integrating commercial assets acquired from Takeda into NPS and expanding the company's international presence.

Matkovits served as Chief Operating Officer for ContraVir Pharmaceuticals from 2015 to 2018, where they built and oversaw a significant portion of the company, including clinical development, regulatory affairs, pharmaceutical development, manufacturing, quality, and program management. Theresa also represented ContraVir to key internal and external stakeholders and effectively communicated the company's value story and clinical data.

In 2018, Matkovits became the Chief Development Officer of Matinas BioPharma, a public biopharmaceutical company focused on developing a proprietary drug-delivery platform for infectious diseases, inflammation, and oncology. In this role, they served as the clinical face of the company to the investor community, delivering clinical and scientific perspectives on the value proposition of the company's portfolio.

Throughout their career, Matkovits has also held board positions and served as a director for various organizations, including GoodCap Pharmaceuticals Inc., Appili Therapeutics, BioSurplus, Aradigm Corporation, and Center Point Clinical Services LLC.

Before their appointments in the biopharmaceutical industry, Matkovits founded their own company, Matkovits Enterprises, LLC, in 2013.

Overall, Matkovits has a proven track record of driving growth and success in the biopharmaceutical industry through their leadership and expertise in clinical development, regulatory affairs, and strategic planning.

Theresa Matkovits, Ph.D., obtained their Bachelor of Arts (B.A.) degree in Biology, General from Alfred University, where they studied from 1985 to 1989. Subsequently, they pursued their academic endeavors and earned a Doctor of Philosophy (Ph.D.) degree in Biochemistry and Molecular Biology from the University of Medicine and Dentistry of New Jersey - New Jersey Medical School. This was a five-year program, completed between 1989 and 1994.